The pH of Piperazine Derivative Solutions Predicts Their Utility as Transepithelial Permeation Enhancers

Molecular Pharmaceutics

Volumn 13, Issue 2, 2016, Pages 578-585

  Lamson, Nicholas G ^a   Cusimano, Gabrielle ^a   Suri, Kanika ^a   Zhang, Anna ^a   Whitehead, Kathryn A ^a  

^a CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

Caco 2; epithelial delivery; oral delivery; paracellular permeability; permeation enhancer; piperazine

Indexed keywords

AMINE; HYDROCARBON; PENETRATION ENHANCING AGENT; PIPERAZINE DERIVATIVE;

ALKALINITY; ARTICLE; CACO 2 CELL LINE; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE EPITHELIUM; MOLECULAR SIZE; PH; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TRANSEPITHELIAL RESISTANCE; CACO-2 CELL LINE; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; INTESTINE MUCOSA; ORAL DRUG ADMINISTRATION; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, ORAL; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL MUCOSA; PIPERAZINES;

EID: 84957309632     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00803     Document Type: Article

References (32)

1. Agrawal, U.; Sharma, R.; Gupta, M.; Vyas, S. P. Is Nanotechnology a Boon for Oral Drug Delivery? Drug Discovery Today 2014, 19 (10) 1530-1546 10.1016/j.drudis.2014.04.011
2. Mrsny, R. J. Oral Drug Delivery Research in Europe J. Controlled Release 2012, 161 (2) 247-253 10.1016/j.jconrel.2012.01.017
3. Hamman, J. H.; Enslin, G. M.; Kotze, A. F. Oral Delivery of Peptide Drugs BioDrugs 2005, 19 (3) 165-177 10.2165/00063030-200519030-00003
4. Aungst, B. J. Intestinal Permeation Enhancers J. Pharm. Sci. 2000, 89 (4) 429-442 10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J
5. Friend, D. R. Drug Delivery to the Small Intestine Current gastroenterology reports 2004, 6 (5) 371-376 10.1007/s11894-004-0052-z
6. Bourdet, D. L.; Pollack, G. M.; Thakker, D. R. Intestinal Absorptive Transport of the Hydrophilic Cation Ranitidine: A Kinetic Modeling Approach to Elucidate the Role of Uptake and Efflux Transporters and Paracellular vs. Transcellular Transport in Caco-2 Cells Pharm. Res. 2006, 23 (6) 1178-1187 10.1007/s11095-006-0204-y
7. Whitehead, K.; Mitragotri, S. Mechanistic Analysis of Chemical Permeation Enhancers for Oral Drug Delivery Pharm. Res. 2008, 25 (6) 1412-1419 10.1007/s11095-008-9542-2
8. Sonaje, K.; Chuang, E. Y.; Lin, K. J.; Yen, T. C.; Su, F. Y.; Tseng, M. T.; Sung, H. W. Opening of Epithelial Tight Junctions and Enhancement of Paracellular Permeation by Chitosan: Microscopic, Ultrastructural, and Computed-Tomographic Observations Mol. Pharmaceutics 2012, 9 (5) 1271-1279 10.1021/mp200572t
9. Schmidt, E.; Kelly, S. M.; van der Walle, C. F. Tight Junction Modulation and Biochemical Characterisation of the Zonula Occludens Toxin C-and N-Termini FEBS Lett. 2007, 581 (16) 2974-2980 10.1016/j.febslet.2007.05.051
10. Hu, Y. J.; Wang, Y. D.; Tan, F. Q.; Yang, W. X. Regulation of Paracellular Permeability: Factors and Mechanisms Mol. Biol. Rep. 2013, 40 (11) 6123-6142 10.1007/s11033-013-2724-y
11. Whitehead, K.; Karr, N.; Mitragotri, S. Safe and Effective Permeation Enhancers for Oral Drug Delivery Pharm. Res. 2008, 25 (8) 1782-1788 10.1007/s11095-007-9488-9
12. Whitehead, K. a.; Dorkin, J. R.; Vegas, A. J.; Chang, P. H.; Veiseh, O.; Matthews, J.; Fenton, O. S.; Zhang, Y.; Olejnik, K. T.; Yesilyurt, V.; Chen, D.; Barros, S.; Klebanov, B.; Novobrantseva, T.; Langer, R.; Anderson, D. G. Degradable Lipid Nanoparticles with Predictable in Vivo siRNA Delivery Activity Nat. Commun. 2014, 5, 1-10 10.1038/ncomms5277
13. Bali, a; Reddy, a C. D. K. Synthesis and Evaluation of Meta Substituted 1-(aryloxypropyl)-4- (chloroaryl) Piperazines as Potential Atypical Antipsychotics Med. Chem. Res. 2013, 22 (1) 382-391 10.1007/s00044-012-0038-6
14. Severinsen, K.; Kraft, J. F.; Koldso, H.; Vinberg, K. a; Rothman, R. B.; Partilla, J. S.; Wiborg, O.; Blough, B.; Schiott, B.; Sinning, S. Binding of the Amphetamine-like 1-Phenyl-Piperazine to Monoamine Transporters ACS Chem. Neurosci. 2012, 3 (9) 693-705 10.1021/cn300040f
15. Albert, A.; Serjeant, E. P. Determination of Ionization Constants by Potentiometric Titration Using a Glass Electrode. In The Determination of Ionization Constants: A Laboratory Manual; Chapman and Hall: London, 1984; pp 14-38.
16. Pinto, M.; Robine-Leon, S.; Appay, M.-D.; Kedinger, M.; Triadou, N.; Dussaulx, E.; Lacroix, B.; Simon-Assmann, P.; Haffen, K.; Fogh, J.; Zweibaum, A. Enterocyte-like Differentiation and Polarization of the Human Colon Carcinoma Cell Line Caco-2 in Culture Biol. Cell 1983, 47 (323) 323-330
17. Sambuy, Y.; De Angelis, I.; Ranaldi, G.; Scarino, M. L.; Stammati, a.; Zucco, F. The Caco-2 Cell Line as a Model of the Intestinal Barrier: Influence of Cell and Culture-Related Factors on Caco-2 Cell Functional Characteristics Cell Biol. Toxicol. 2005, 21 (1) 1-26 10.1007/s10565-005-0085-6
18. Press, B.; Di Grandi, D. Permeability for Intestinal Absorption: Caco-2 Assay and Related Issues Curr. Drug Metab. 2008, 9 (9) 893-900 10.2174/138920008786485119
19. Volpe, D. A. Variability in Caco-2 and MDCK Cell-Based Intestinal Permeability Assays J. Pharm. Sci. 2008, 97 (2) 712-725 10.1002/jps.21010
20. Shen, L.; Weber, C. R.; Raleigh, D. R.; Yu, D.; Turner, J. R. Tight Junction Pore and Leak Pathways: A Dynamic Duo Annu. Rev. Physiol. 2011, 73, 283-309 10.1146/annurev-physiol-012110-142150
21. Yamashita, S.; Furubayashi, T.; Kataoka, M.; Sakane, T.; Sezaki, H.; Tokuda, H. Optimized Conditions for Prediction of Intestinal Drug Permeability Using Caco-2 Cells Eur. J. Pharm. Sci. 2000, 10 (3) 195-204 10.1016/S0928-0987(00)00076-2
22. Yee, S. In Vitro Permeability across Caco-2 Cells (colonic) Can Predict in Vivo (small Intestinal) Absorption in Man-Fact or Myth Pharm. Res. 1997, 14, 763-766 10.1023/A:1012102522787
23. Artursson, P.; Palm, K.; Luthman, K. Caco-2 Monolayers in Experimental and Theoretical Drug Transport Predictions of Drug Transport Adv. Drug Delivery Rev. 1996, 46 (96) 27-43
24. Artursson, P.; Karlsson, J. Correlation between Oral Drug Absorption in Humans and Apparent Drug Permeability Coefficients in Human Intestinal Epithelial (CACO-2) Cells Biochem. Biophys. Res. Commun. 1991, 175 (3) 880-885 10.1016/0006-291X(91)91647-U
25. Konsoula, R.; Barile, F. a. Correlation of in Vitro Cytotoxicity with Paracellular Permeability in Caco-2 Cells Toxicol. In Vitro 2005, 19 (5) 675-684 10.1016/j.tiv.2005.03.006
26. Khalili, F.; Henni, A.; East, A. L. L. PKa Values of Some Piperazines at (298, 303, 313, and 323) K J. Chem. Eng. Data 2009, 54, 2914-2917 10.1021/je900005c
27. Konishi, Y. K.; Kubo, K. K.; Shimizu, M. S. Biosci., Biotechnol., Biochem. 2003, 67 (9) 2014-2017 10.1271/bbb.67.2014
28. Nagahara, N.; Tavelin, S.; Artursson, P. Contribution of the Paracellular Route to the pH-Dependent Epithelial Permeability to Cationic Drugs J. Pharm. Sci. 2004, 93 (12) 2972-2984 10.1002/jps.20206
29. Hinuma, K.; Matsuda, J.; Tanida, N.; Hori, S.; Tamura, K. N-Nitrosamines in the Stomach with Special Reference to in Vitro Formation, and Kinetics after Intragastric or Intravenous Administration in Rats Experiment I: In Vitro Formation Formation of NAs In Vitro Formation of NAs Was Examined by Japanese Society of Gastroenterology 1990, 25 (4) 417-424
30. Klein, R. G.; Schmezer, P.; Hermann, R.; Waas, P.; Spiegelhalder, B.; Bartsch, H. Strong Nasal Carcinogenicity and Genotoxicity of 1-Nitroso-4-Methylpiperazine after Low Dose Inhalation in Rats Carcinogenesis 1999, 20, 1629-1631 10.1093/carcin/20.8.1629
31. Sheng, J. J.; McNamara, D. P.; Amidon, G. L. Toward an In Vivo Dissolution Methodology: A Comparison of Phosphate and Bicarbonate Buffers Mol. Pharmaceutics 2009, 6 (1) 29-39 10.1021/mp800148u
32. Tsume, Y.; Langguth, P.; Garcia-Arieta, A.; Amidon, G. L. In Silico Prediction of Drug Dissolution and Absorption with Variation in Intestinal pH for BCS Class II Weak Acid Drugs: Ibuprofen and Ketoprofen Biopharm. Drug Dispos. 2012, 33 (7) 366-377 10.1002/bdd.1800